Pharming Group NV

Pharming Group NV posts a 27 % revenue jump in 2025, fueled by Ruconest and Joenja, while keeping costs tight and generating positive cash‑flow—boosting its rare‑disease leadership.

Pharming Group’s FDA CRL for Joenja® in children highlights dosage & testing hurdles that could delay pediatric launch and impact investor confidence.

Pharming Group NV: biotech leader in rare‑disease therapies sees high P/E yet stagnant growth; investors weigh its Ruconest success against limited new breakthroughs.

Pharming Group NV’s rare‑disease focus and strategic partnerships drive a growing protein‑therapy pipeline, offering investors insight into future growth potential.

Pharming Group NV is a pioneering biotechnology company that is addressing rare diseases and unmet medical needs through innovative therapies and strategic partnerships.